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Abstract 
Objective: Octacalcium phosphate (OCP) and collagen (col) composite (OCPcol) 
demonstrated superior bone regeneration properties, and its commercialization appears to 
be forthcoming. As a practical medical material for new combination products, we 
developed a freeze-dried composite with OCPcol and teriparatide (TPTD) (OCPcolTPTDf), 
and investigated its bone regenerative properties. 
Materials and Methods: A disk of OCPcol was made by mixing OCP granules and 
atelocollagen for medical use. Then, OCPcolTPTDf was prepared by impregnation of the 
OCPcol disc with 1.0 µg or 0.1 µg of TPTD solution (OCPcolTPTDf 1.0 and 
OCPcolTPTDf 0.1, respectively) followed by lyophilization. In vitro release profiles of 
TPTD from OCPcolTPTDf were determined using an enzyme-linked immunosorbent assay. 
Implantation of OCPcolTPTDf or OCPcol was carried out for a rat critical-sized calvarial 
defect. And five defects in each group were collected after 12 weeks of implantation. 
Results: The retention–release profiles of TPTD from OCPcolTPTDf supported a higher 
degree of retention of TPTD. Radiographic, histologic, and histomorphometric 
examinations indicated that regenerated bone was filled in most of the defects of the 
OCPcolTPTDf. Additionally, the OCPcolTPTDf groups showed significantly enhanced 
bone regeneration compared with the OCPcol group. 
Conclusions: These results suggested that this newly developed bone regenerative composite 
could be a practical medical material. 
 
Keywords: Bone tissue engineering, Calcium phosphate, Collagen, Parathyroid hormone 
 
Running title: Freeze-dried composite of OCPcol and teriparatide  
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Introduction 
Hydroxyapatite (HA: Ca10(PO4)6(OH)2) or β-tricalcium phosphate (β-TCP: Ca3(PO4)2) is 
one of calcium phosphates (CaPs), and their synthetic type have already been developed and 
widely applied for bone substitutes of clinical cases (Habraken et al., 2016, Kokubo et al., 
2003). Octacalcium phosphate (OCP: Ca8H2(PO4)6 • 5H2O) is one of CaPs and a synthetic 
bioresorbable material as well as β-TCP. OCP has been suggested to be a precursor of 
biological apatite in bones (Brown et al., 1962, Crane et al., 2006), and it has demonstrated 
significant bone formation abilities compared with other bone replacement materials 
(Kamakura et al., 2002). Although OCP has limitation of moldability and handling 
performance, development of OCP and collagen (col) composite (OCPcol) enabled to 
overcome its limitations (Kamakura et al., 2006). In preclinical studies, OCPcol demonstrated 
significant bone formation to OCP granules and other commercialized bone replacement 
materials in critical sized bone defects (Kamakura et al., 2007a, Kamakura et al., 2006, 
Tanuma et al., 2013). Additionally, OCPcol has achieved stable bone regeneration without cell 
transplantation, and the improvement of physiological bone remodeling is expected 
(Kamakura et al., 2006, Tanuma et al., 2013, Matsui et al., 2014). Moreover, OCPcol has good 
usability and cost performance (Iibuchi et al., 2010). After preclinical studies, a 
physician-initiated clinical study was carried out for extraction sockets of teeth and cyst holes, 
which demonstrated the safety and efficacy of OCPcol (Kawai et al., 2014, Kawai et al., 2017, 
Kawai et al., 2016). Recently, a sponsor-initiated clinical trial on OCPcol was completed, 
which was registered with the International Clinical Trials Registry in World Health 
Organization (JPRN-UMIN000018192), and commercialization on bone defects of oral region 
including sinus floor elevation and alveolar clefts is expected in 2018. However, independent 
use of OCPcol has limited bone regeneration, thus, the development of more trustworthy bone 
regenerative materials is awaited (Miura et al., 2012). 
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Metabolism and functions of calcium and phosphate is fundamentally regulated by 
parathyroid hormone (PTH) (Sibai et al., 2011). And teriparatide (TPTD) which is a 
recombinant form of PTH consisting of bioactive portion of N-terminal fragment comprising 
34 amino acids (Niall et al., 1974). TPTD has a unique mechanism, and its continuous 
administration led to a decrease in bone volume, whereas its intermittent administration 
conducted to increase trabecular bone (Jilka et al., 1999, Tam et al., 1982). Furthermore, TPTD 
is the only authorized anabolic drug for the treatment of osteoporosis by the U.S. Food and 
Drug Administration (Morimoto et al., 2014).  
Several preclinical studies were performed to repair the critical sized bone defects by 
applying scaffolds, such as an absorbable collagen sponge (Stancoven et al., 2013), 
demineralized bone matrix (Pensak et al., 2015, Stancoven et al., 2013), β-TCP (Yun et al., 
2010), or poly-lactic acid (Jacobson et al., 2011) with intermittent subcutaneous administration 
of TPTD. Although high amounts of TPTD compared with that for the treatment for 
osteoporosis in clinical situations, were administrated in these studies, some researchers 
reported a significant effect (Jacobson et al., 2011, Yun et al., 2010), whereas others failed to 
find any effect (Pensak et al., 2015, Stancoven et al., 2013). 
Recently, it was reported that the local single administration of TPTD (20 µg) with a 
collagen sponge is effective for repair of a rat calvarial defect (Auersvald et al., 2017). It was 
revealed that OCPcol with a local single administration of TPTD (1 or 0.1 µg) which is a low 
dosage similar to that for the treatment for osteoporosis, enhanced bone repair of the 
critical-sized bone defect (Kajii et al., 2017), and its modality might be practical for improving 
effective bone regeneration safely. However, it would be more versatile as a medical material if 
a freeze-dried composite with OCPcol and TPTD (OCPcolTPTDf) was created. Also, β-TCP is 
a synthetic bioresorbable material which has been a commonly used in maxillofacial lesion 
(Trombelli et al., 2014). Although OCP is a synthetic bioresorbable material as well as β-TCP, 
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OCP has unique features unlike β-TCP. It stimulated osteogenesis by osteoblastic cells and/or 
committed osteoprogenitors (Anada et al., 2008). And the implanted OCP is more resorbable 
than the implanted β-TCP (Kamakura et al., 2002), and it can serve as a core for initiating bone 
regeneration if implanted in a bone defect (Kamakura et al., 2001). Therefore, β-TCP is applied 
as a control of OCP, and the difference of bone regeneration with freeze-dried composite 
TPTD with OCPcol or β-TCP was investigated if implanted in a rat calvarial critical-sized bone 
defect. 
 
Materials and Methods  
1. Preparation of OCPcol and β-TCPcol 
The preparation of OCPcol and β-TCPcol was described previously (Kamakura et al., 
2007a). Briefly, OCP was prepared by direct precipitation (Suzuki et al., 1991), and sieved 
granules (particle sizes of 300 - 500 µm) of OCP were produced. Commercially available 
sintered β-TCP (Osferion, Olympus Terumo Biomaterials Corp., Tokyo, Japan) was purchased 
and sieved granules (particle sizes of 300–500 µm) of β-TCP were prepared for the fabrication 
of β-TCPcol. And, it was purchased the powder of lyophilized atelocollagen (NMP collagen 
PS; Nippon Meat Packers, Tsukuba, Ibaraki, Japan) which was digested by pepsin from the 
porcine dermis. After OCP granules were mixed with concentrated collagen, and it was 
completed 77% of the weight percentage of OCP in OCPcol. Likewise, the same volume of 
β-TCP granules as well as OCP granules were added to concentrated collagen and mixed. The 
OCPcol or β-TCPcol mixture was then lyophilized, and a disk was molded (9 mm diameter, 1.5 
mm thickness). The OCPcol or β-TCPcol disks were prepared by a dehydrothermal treatment 
(150°C, 24 h) in a vacuum drying oven.  
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2. Preparation of OCPcolTPTD composite and β-TCPcolTPTD composite 
Firstly, TPTD solution was prepared. Chemically-synthesized lyophilized teriparatide 
acetate (TERIBONETM Inj. 56.5 µg; Asahi Kasei Pharma Corp., Tokyo, Japan) was 
reconstituted and made a solution of 56.5 µg/ml. The process for the preparation of OCPcol 
disks combined with 1.0 µg of TPTD (OCPcolTPTDf 1.0) was as follows: an OCPcol disk was 
placed in 48 well plate, and 17.7 µl of TPTD solution (56.5 µg/ml) was impregnated into the 
OCPcol disk. The OCPcolTPTDf 1.0 disks were then lyophilized, followed by sterilization 
using electron beam irradiation (22 kGy). Likewise, 17.7 µl of TPTD solution (5.65 µg/ml) 
was transferred onto an OCPcol disk to prepare OCPcol disks combined with 0.1 µg of TPTD 
(OCPcolTPTDf 0.1). OCPcol disks without TPTD (OCPcol) were also sterilized by electron 
beam irradiation (22 kGy). And the same procedures were performed for β-TCPcol disks, and 
β-TCPcol disks combined with 1.0 µg or 0.1 µg of TPTD (β-TCPcolTPTDf 1.0, 
β-TCPcolTPTDf 0.1, respectively) or β-TCPcol without TPTD (β-TCPcol) were prepared.  
 
3. Retention/release of TPTD from OCPcolTPTDf or β-TCPcolTPTDf 
To examine the pattern of retention/release from OCPcolTPTDf or β-TCPcolTPTDf, 
each disk of OCPcolTPTDf 1.0, OCPcolTPTDf 0.1, β-TCPcolTPTDf 1.0, or β-TCPcolTPTDf 
0.1 was placed into a 12-well plate (SUMILON, SUMITOMO BAKELITE Co., LTD, Tokyo, 
Japan) and soaked with 2.0 ml of saline containing 0.05% benzalkonium chloride, which was 
used to suppress the adsorption of TPTD onto the plate surface. The plates were placed in an 
incubator at 37°C. The supernatants were collected, and the plates were replenished with fresh 
saline containing 0.05% benzalkonium chloride at 1, 3, 7, 14, and 28 days. The concentration 
of TPTD released into the saline at each time point was determined by analyzing the 
supernatant using an enzyme-linked immunosorbent assay (ELISA) with a TPTD Assay Kit 
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(PTH 1-34 Teriparatide PK ELISA, Somru Bioscience, Charlottetown, Canada) and TPTD 
standards. Two specimens were used per group. 
 
4. Implantation procedure 
Twelve-week-old of male Wistar strain rats (SLC Corp.; Hamamatsu, Shizuoka, Japan) 
were used in this study. All procedures (2013-Biomedical Engineering Animal -003) were 
permitted by the Animal Research Committee of Tohoku University, which followed the 
principles of laboratory animal care and national laws. Body weight of rats were measured and 
they were anesthetized by dexmedetomidine hydrochloride (0.15–0.4 mg/kg), butorphanol 
tartrate (2.5–5 mg/kg), and midazolam (2 mg/kg) through intraperitoneal injection. After a 
parietal skin incision and ablation of the periosteum of the calvarium, 9 mm in diameter of 
standardized critical-sized defect was trephined in the calvarium (Kajii et al., 2018).  
Randomly selected thirty experimental rats were separated into six groups (1. 
OCPcolTPTDf 1.0, 2. OCPcolTPTDf 0.1, 3. OCPcol, 4. β-TCPcolTPTDf 1.0, 5. 
β-TCPcolTPTDf 0.1, and 6. β-TCPcol) and five defects were treated in each group. Each type 
of a disk was implanted into the trephine defect after saline irrigation of the trephine defect. 
Finally, the treated periosteum and skin were relocated and sutured, and subcutaneous injection 
of cephalexin (15 mg/kg) was made to prevent infection. These experimental animals were 
euthanized 12 weeks after implantation. The total amounts of TPTD in this study were 3.93 ± 
0.08 µg/kg in the OCPcolTPTDf 1.0 group, 0.38 ± 0.01 µg/kg in the OCPcolTPTDf 0.1 group, 
3.84 ± 0.14 µg/kg in the β-TCPcolTPTDf 1.0 group, and 0.38 ± 0.02 µg/kg in the 
β-TCPcolTPTDf 0.1 group, when adapted to the average weight of each group at implantation. 
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5. Micro-computed tomography (micro-CT) examination 
At 4 and 12 weeks after implantation, examination of rat calvarium was made by using an 
in vivo micro-CT system (Latheta LCT-200; Hitachi Aloka Medical, Tokyo, Japan) during 
intraperitoneal injection of sodium pentobarbital (50 mg/kg) (Kajii et al., 2017b). After 
measuring body weight, the treated defects were scanned in 120 µm thickness for slices and 60 
µm pixel size. The images of micro-CT were acquired in standardized conditions (50 kVp, 500 
μA, 3.6 ms). After finishing the CT analysis of 12 weeks, the experimental animals were 
euthanized by intraperitoneal injection of overdosed sodium pentobarbital. Then, the samples 
were resected with the surrounding bone, and the tissue were immersed with 4% 
paraformaldehyde in 0.1 M phosphate-buffered saline (PBS), pH 7.4. 
 
6. Radiographic analysis 
Radiography of the skulls were taken by a microradiography unit (Softex M-60, Softex 
Co., Ltd., Ebina, Kanagawa, Japan) with X-ray film (FR; Fuji photo film, Tokyo, Japan) in 
standardized conditions (45 kV, 1.5 mA, 2 min.), in which the OCPcol disks before 
implantation showed no radiopacity 
 
7. Tissue preparation and a quantitative micrograph analysis   
After the radiographs had been taken, the samples were decalcified in 10% EDTA in 0.01 
M phosphate buffer, pH 7.4 at 4°C for 2–4 weeks. After embedding in paraffin, coronal section 
of the center of the defect was prepared. Hematoxylin and eosin (HE) staining was made and 
taken photographs by a photomicroscope (Leica DM2500; Leica Microsystems Japan, Tokyo, 
Japan). The histomorphometric analysis used in this study have been previously described 
(Kamakura et al., 2007a, Kamakura et al., 2002). The percentage of newly formed bone in the 
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defect (n-Bone%) was calculated as the area of newly formed bone/area of the original defect × 
100. n-Bone% was computed by public-domain software (ImageJ 1.43). 
 
8. Statistical analysis 
Statistical analysis of n-Bone% was performed by using software (Excel v. X.; Microsoft 
Co., Redmond, WA), and the values of means ± standard deviation (SD) are reported. The 
chi-squared test and Bartlett’s test were used to examine whether each group had a normal 
distribution and the homogeneity of variance across samples. To compare means among 
groups, one-way analysis of variance (ANOVA) was used and p < 0.05 was accepted 
significance. If the mean values were significantly different, a post-hoc test was performed by 
Tukey–Kramer multiple comparison analysis. 
 
Results 
1. Retention/release of TPTD from OCPcolTPTDf or β-TCPcolTPTDf 
The release profiles of TPTD from OCPcolTPTDf or β-TCPcolTPTDf are shown in 
Figure 1. The release pattern of TPTD from OCPcolTPTDf 1.0 or β-TCPcolTPTDf 1.0 resulted 
in approximately 40% initial release within 1 day, followed by the release of smaller amounts 
over 7 days. Then, the release of TPTD then plateaued until 28 days, with a total of 46–49% of 
TPTD released. In the cases of OCPcolTPTDf 0.1 or β-TCPcolTPTDf 0.1, about 20% initial 
release was observed within 1 day, followed by smaller amounts over 7 days. The release of 
TPTD then plateaued until 28 days, with a total 24–25% of TPTD released. 
 
2. Micro-CT analysis and radiographic examinations  
Figure 2 indicates the central part of the defect of coronal sections. Although OCPcol 
disks had negligible radiopacity (Kamakura et al., 2007b), implanted OCPcol was radiopaque 
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because of conversion of the apatitic phase or regenerating bone (Iibuchi et al., 2010). In the 
OCPcolTPTDf 1.0 and OCPcolTPTDf 0.1 groups, radiopaque figures were observed in most 
of the defect including the central part at 4 weeks (Fig. 2). The uniform plate-like radiopacity 
was continuous with the original bone. The level of radiopacity increased with time, indicating 
repair of the defects. The boundary between the margin of the defect and the pre-existing bone 
became indistinguishable, and the radiopacity was comparable to that of the pre-existing bone 
(Fig. 2 and 3). 
In the OCPcol group, most of the defect was occupied by scattered small radiopaque 
masses at 4 weeks after implantation (Fig. 2). These became uniform, small scattered 
radiopaque masses, which were intermingled in the defect at 12 weeks after implantation. The 
radiopacity was comparable to that of the pre-existing bone (Fig. 2 and 3). In the 
β-TCPcolTPTDf 1.0 group, granulous radiopacity was predominant in the defect at 4 weeks. 
Although this pattern increased with plate-like radiopacity, which extended from the defect 
margin at 12 weeks, the central part of the defect seemed to remain radiolucent with granules of 
β-TCP (Fig. 2 and 3). In the β-TCPcolTPTDf 0.1 group, granulous radiopacity was 
predominant in the defects at 4 and 12 weeks (Fig. 2 and 3). In the β-TCPcol group, granulous 
and cluster-like radiopacity were intermingled at 4 weeks, and the radiopacity increased at 12 
weeks (Fig. 2 and 3). 
 
3. Histological results of implants  
Figures 4 and 5 indicates the side of the skin is upper and side of the dura mater is lower. In 
the OCPcolTPTDf 1.0 and OCPcolTPTDf 0.1 groups, newly formed bone was occupied in 
most of the defect, and the thickness of the new bone was similar to that of the pre-existing 
bone (Fig. 4). In addition, the boundary between the margin of the defect and the pre-existing 
bone was indistinguishable, and the implanted OCPcol was almost resorbed (Fig. 4 and 5). A 
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cortical bone-like structure was associate with some part of regenerated bone, and invasion of 
blood vessels and the formation of bone marrow was observed. In the OCPcol group, newly 
formed bone was filled in a large part of the defect, and most of the implanted OCPcol was 
resorbed. Some of the new bone which had united with implanted OCPcol, indicated a mosaic 
pattern (Fig. 4 and 5). In the β-TCPcolTPTDf 1.0, β-TCPcolTPTDf 0.1, and β-TCPcol groups, 
newly formed bone was filled in a large part of the defect, although most of the regenerated 
bone originated from the margin of the defect. A part of the implanted β-TCP granules was 
surrounded and replaced by newly formed bone. In addition, the implanted β-TCP granules, 
which were surrounded by fibrous connective tissue, were abundant in the bone defect (Fig. 4 
and 5). 
 
4. Histomorphometric examination 
The n-Bone% in the OCPcolTPTDf 1.0, OCPcolTPTDf 0.1, and OCPcol groups were 
58.6 ± 2.7%, 56.1 ± 3.0%, and 42.3 ± 4.3%, respectively. Furthermore, those of the 
β-TCPcolTPTDf 1.0, β-TCPcolTPTDf 0.1, and β-TCPcol groups were 36.8 ± 4.3%, 27.5 ± 
10.0%, and 32.4 ± 9.1%, respectively. The mean values of n-Bone% indicated significant 
differences (ANOVA, P = 6.3 × 10-8), and Tukey–Kramer multiple comparison analysis 
showed significant differences between the OCPcolTPTDf 1.0 group and the other four groups 
(OCPcol, β-TCPcolTPTDf 1.0, β-TCPcolTPTDf 0.1, and β-TCPcol), between the 
OCPcolTPTDf 0.1 group and the other four groups (OCPcol, β-TCPcolTPTDf 1.0, 
β-TCPcolTPTDf 0.1, and β-TCPcol), and between the OCPcol and β-TCPcolTPTDf 0.1 
groups (Fig. 6). 
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Discussion 
Radiographic analyses including micro-CT, histologic, and histomorphometric analysis 
indicated that OCPcolTPTDf significantly enhanced bone regeneration more than OCPcol 
alone. In the OCPcolTPTDf groups, radiopaque figures were observed in most of the defect at 
4 weeks, which increased and extended throughout the whole defect with time. New bone had 
the same thickness as the original bone, and it extended over the central part of the defect. In 
addition, some of the bone showed a cortical bone-like structure after maturation. In the 
OCPcol group, the newly formed bone was smaller than in the OCPcolTPTD groups, although 
it had integrated with implanted OCPcol. OCP stimulated bone regeneration by osteoblastic 
cells and/or committed osteoprogenitors (Anada et al., 2008) and TPTD enhanced osteogenic 
and osteoclastic activities (Morimoto et al., 2014). Therefore, OCPcol combined with TPTD 
through lyophilization could exhibit a synergistic effect with OCPcol and TPTD by increasing 
bone regeneration. 
The β-TCPcolTPTDf groups (β-TCPcolTPTDf 1.0, β-TCPcolTPTDf 0.1) showed 
insufficient bone regeneration compared with the OCPcolTPTDf groups, suggesting that 
OCPcolTPTDf could enhance bone regeneration more than β-TCPcolTPTDf. Bone 
regeneration with OCPcolTPTDf originated from the OCPcolTPTDf itself and the margin of 
the defect, whereas that with β-TCPcolTPTDf was predominantly from the margin of the 
defect. This could be related to OCPcol nucleated bone regeneration if implanted into rodent 
critical sized calvarial defects (Kamakura et al., 2007a, Kamakura et al., 2006). Moreover, no 
significant differences in the newly formed bone were observed between the β-TCPcolTPTDf 
groups and β-TCPcol group. In these groups, the implanted β-TCP regenerated bone was 
intermingled with regenerated bone and fibrous connective tissue in the created defect, 
although granulous radiopacity changed to plate-like radiopacity with time. In addition, newly 
formed bone predominantly developed from the margin of the defect. It was considered that 
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β-TCP have not actively involved in the differentiation of osteoblasts, and the degradation of 
β-TCPcol which might be released TPTD was slower than OCPcol. Hence, it might be difficult 
to regenerate bone by β-TCPcol if TPTD was released around β-TCPcol, because there were 
few osteoprogenitor cells around β-TCPcol. It was correlated the histological finding that most 
of the regenerated bone originated from the margin of the defect in three β-TCPcol groups. 
This indicated that the synergistic effect could be restricted by the combination with β-TCPcol 
and TPTD. Consequently, a combination with OCPcol and TPTD could be specific for the 
synergistic effect of bone regeneration. 
The release profiles of TPTD from OCPcolTPTDf 1.0 or β-TCPcolTPTDf 1.0 indicated 
that half of the TPTD was released within 7 days, and the other half remained at 28 days. In 
addition, that of OCPcolTPTDf 0.1 or β-TCPcolTPTDf 0.1 demonstrated about one-quarter of 
the TPTD was released within 7 days, and three-quarters remained at 28 days. These results 
resembled the release profile of bone morphogenic protein-2 (BMP-2) from Zein 
polydopamine TiO2 BMP-2, which could have triggered early differentiation markers and 
activated the expression of late osteogenic markers (Babitha et al., 2017). The release pattern of 
OCPcolTPTDf or β-TCPcolTPTDf suggested that TPTD was retained in OCPcol or β-TCPcol 
after initial release. It indicated that secondary release of TPTD from implant would be 
depended on the degradation of OCPcol or β-TCPcol. Because OCPcol was more resorbable 
than β-TCPcol (Kamakura et al., 2007a), the retained TPTD in OCPcol might be released more 
than that in β-TCPcol. Consequently, these procedures might enhance bone regeneration of 
OCPcolTPTDf more than β-TCPcolTPTD. In addition, this study demonstrated that bone 
regeneration was enhanced more with OCPcolTPTDf than with OCPcol. There could be a 
similar synergistic effect of OCPcol impregnated with TPTD, as reported recently (Kajii et al., 
2017). However, bone regeneration with β-TCPcolTPTDf showed no significant differences 
compared with β-TCPcol, suggesting that there may be no synergistic effect of β-TCPcol and 
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TPTD. It was reported that OCP is capable of inducing the differentiation of osteoblastic cell 
lineages (Anada et al., 2008), and OCP incubated in rat serum proteins adsorbed bone 
formation-related proteins (Kaneko et al., 2011). In addition, it was observed a decrease in the 
concentration of Ca2+ and increase in inorganic phosphate during apatitic conversion from 
OCP (Anada et al., 2008). Therefore, it might be related to the difference in bone regenerative 
properties between OCPcol and β-TCPcol, and the behavior of osteogenic markers with 
OCPcolTPTDf should be investigated further. 
In this study, no significant difference was observed between bone regeneration with 
OCPcolTPTDf 1.0 and that with OCPcolTPTDf 0.1 as well as bone regeneration with OCPcol 
with the local single administration of TPTD solution (1.0 µg or 0.1 µg) (Kajii et al., 2017). It 
could be considered that OCPcol combined with TPTD could not enhance bone regeneration in 
a dose-dependent manner. It suggested that the dose of 0.1 µg of TPTD in this defect might be 
sufficient to regenerate bone by OCPcolTPTDf. It is well known that usually administered 
doses of TPTD to patients with osteoporosis is about 1 μg/kg/week (TeriboneTM) or 0.2–0.5 
μg/kg/day (Forteo®). And osteosarcoma might be occurred, if TPTD was subcutaneously 
given at 13.6 µg/kg/day for 2 years (total amount of about 10,000 µg/kg) (Watanabe et al., 
2012). Because TPTD administered in this study (total amount of approximately 0.38–3.93 
µg/kg) was distinctly lower dose than other previous studies as a single or total amount, 
OCPcolTPTDf should be a safe material for practical use with excellent bone regeneration. In 
order to be acceptable for clinical applications as OCPcolTPTDf, the influence of the dose of 
TPTD should be further investigated in larger animal studies. 
In this study, it was confirmed that an OCPcol and TPTD composite (OCPcolTPTDf) 
could enhance bone regeneration as well as OCPcol with the single local administration of 
TPTD (OCPcolTPTDd) (Kajii et al., 2017), and these two materials significantly enhanced 
bone regeneration more than OCPcol alone. Compared with OCPcolTPTDd, OCPcolTPTDf 
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has several advantages. Because there is no need to prepare a solution of TPTD during the 
implantation procedure, the operation will be simpler and more reliable. In addition, 
OCPcolTPTDf has a good storage stability and high versatility. This newly developed OCPcol 
and TPTD composite (OCPcolTPTDf) could be a readily usable medical material and a 
therapeutic alternative for difficult bone defects or urgent surgery. 
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Figure legends 
 
Figure 1: Release profile of TPTD from OCPcol orβ-TCPcol: 
The release of TPTD from OCPcolTPTDf 1.0 or β-TCPcolTPTDf 1.0 resulted in an 
initial release of approximately 40% within 1 day, and a total 46–49% of TPTD was 
released within 28 days. In the case of OCPcolTPTDf 0.1 or β-TCPcolTPTDf 0.1, the 
initial release was approximately 20% within 1 day, and a total 24–25% of TPTD was 
released within 28 days. 
 
Figure 2: Coronal sections examined using micro-computed tomography at the center of 
the created defects: 
In the OCPcolTPTDf 1.0 and OCPcolTPTDf 0.1 groups, most of the defect was occupied 
by radiopaque figures with a thickness similar to that of the pre-existing bone. This 
radiopacity increased with time and repaired the defects. In the OCPcol group, most of 
the defect was occupied by scattered small radiopaque masses at 4 weeks after 
implantation. These masses enlarged and fused with each other over time. In the 
β-TCPcolTPTDf 1.0, β-TCPcolTPTDf 0.1, and β-TCPcol groups, granulous radiopacity 
was predominantly detected in the defect at 4 weeks. This pattern expanded to form a 
plate-like radiopacity, which extended from the margin of the defect at 12 weeks. Arrow 
heads: Defect margin, Bars: 3 mm 
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Figure 3: Radiographic examination:  
In the OCPcolTPTDf 1.0 and OCPcolTPTDf 0.1 groups, most of the defect was occupied by 
uniform radiopacity. The boundary between the margin of the defect and the pre-existing 
bone became indistinguishable. In the OCPcol group, uniform and small scattered 
radiopaque masses intermingled in the created defect. In the β-TCPcolTPTDf 1.0, 
β-TCPcolTPTDf 0.1, and β-TCPcol groups, plate-like and granulous radiopacity 
intermingled in the created defect. Bars: 4 mm 
 
Figure 4: Histological overview of implants:  
In the OCPcolTPTDf 1.0 and OCPcolTPTDf 0.1 groups, newly formed bone was 
occupied in most of the defect, and the thickness of the new bone was similar to that of 
the pre-existing bone.  
In addition, the boundary between the margin of the defect and the pre-existing bone was 
indistinguishable. In the OCPcol group, newly formed bone was filled in a large part of 
the defect. In the β-TCPcolTPTDf 1.0, β-TCPcolTPTDf 0.1, and β-TCPcol groups, most 
of the defect was filled with regenerated bone, whereas the most of the regenerated bone 
originated from the margin of the defect. Hematoxylin eosin stain, Arrow heads: Defect 
margin, Bars: 3 mm 
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Figure 5: Histological findings of implants:  
In the OCPcolTPTDf 1.0 and OCPcolTPTDf 0.1 groups, most of the defect was filled 
with newly formed bone, and most of the implanted OCPcol was resorbed. In the OCPcol 
group, most of the implanted OCPcol was resorbed, and some of the new bone which had 
united with implanted OCPcol, indicated a mosaic pattern In the β-TCPcolTPTDf 1.0, 
β-TCPcolTPTDf 0.1, and β-TCPcol groups, part of the implanted β-TCP granules was 
surrounded and replaced by the newly formed bone. In addition, the implanted β-TCP 
granules were surrounded by abundant fibrous connective tissue is in the bone defect. 
Hematoxylin eosin stain, Asterisks: Implanted OCP or β–TCP, Bars: 200 µm  
 
Figure 6: Quantitative analysis of newly formed bone in defects:  
The percentage of newly formed bone in defects (n-Bone%) ± standard deviation (SD) is 
shown for the OCPcolTPTDf 1.0, OCPcolTPTDf 0.1, OCPcol, β-TCPcolTPTDf 1.0, 
β-TCPcolTPTDf 0.1, and β-TCPcol groups. A significant difference was observed in 
mean values between the OCPcolTPTDf 1.0 group and the other four groups (OCPcol, 
β-TCPcolTPTDf 1.0, β-TCPcolTPTDf 0.1, and β-TCPcol), between the OCPcolTPTDf 
0.1 group and the other four groups (OCPcol, β-TCPcolTPTDf 1.0, β-TCPcolTPTDf 0.1, 
and β-TCPcol), and between the OCPcol and β-TCPcolTPTDf 0.1 groups. Data are 
shown as the means ± SD of five specimens. Asterisks: p < 0.05 
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